Cabergoline (Caber) 0.25 mg

Cabergoline (Caber) 0.25 mg is Hilma Biocare's long-acting dopamine agonist, supplied as 10 tablets. It suppresses prolactin by stimulating dopamine D2 receptors in the pituitary and is one of the most researched prolactin-control medications.

What Cabergoline Is

Cabergoline is an ergot-derived dopamine receptor agonist with high selectivity for the D2 subtype. Dopamine is the natural inhibitor of prolactin secretion, so a D2 agonist reduces prolactin output from the anterior pituitary. Cabergoline's defining feature is its long half-life, which allows sustained suppression from infrequent administration. The 0.25 mg tablet is a standard low-strength presentation.

The History of Cabergoline

Cabergoline was developed by Farmitalia Carlo Erba in the 1980s and introduced as Dostinex in the 1990s for hyperprolactinaemia and prolactin-secreting pituitary tumours. It replaced older ergolines such as bromocriptine in many settings because it was better tolerated and required far less frequent dosing. It has also been studied in Parkinson's disease and in lactation suppression, and it remains a reference dopamine agonist in endocrine research.

How It Works

Cabergoline binds dopamine D2 receptors on lactotroph cells in the pituitary, mimicking the inhibitory effect of endogenous dopamine and reducing prolactin synthesis and release. Its long half-life, measured in days, produces prolonged suppression after a single dose. The drug is extensively metabolised in the liver and excreted in bile and urine. Because it acts centrally rather than on breast tissue, it addresses the source of prolactin production.

What the Research Shows

• Clinical trials established cabergoline as effective for hyperprolactinaemia and prolactinomas.
• Comparative studies show better tolerability and less frequent dosing than bromocriptine.
• Its long half-life has been characterised in pharmacokinetic research.
• Cabergoline has also been investigated in Parkinson's disease and other dopamine-responsive conditions.

Research Context

Long-term cabergoline research has focused on two areas beyond prolactin control: tumour shrinkage in prolactinomas and the risk of cardiac valve fibrosis at high cumulative doses. Imaging studies show that cabergoline can reduce prolactinoma size in a significant proportion of cases, which is why it is preferred over surgery in many situations. The valve signal appears mainly with the much higher doses used in Parkinson's disease, and it has led to recommendations for echocardiographic monitoring in long-term users. Those findings are central to any careful reading of the dopamine-agonist literature.

Strength, Pack and Authentication

The pack contains 10 tablets of 0.25 mg each, sealed in moisture-resistant blister strips inside a printed carton. The carton states the compound, strength and tablet count, and a scratch-off security code inside the box can be checked against Hilma Biocare's records. The compact pack keeps each dose individually protected.

Buying Cabergoline Online

Caber is one of the most searched prolactin-control products. If you are researching cabergoline, comparing Dostinex 0.25 mg products or looking to buy cabergoline online from a trusted Hilma Biocare supplier, this page gives you the full specification, pack size, price and live stock status. Browse more Hilma Biocare hormone-support products at NotNatty.